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Abstract: 
Objective:  To investigate the clinical history of patients with clinical stage II sex cord stromal 
tumors who underwent RPLND at our institution.  
Methods:  Our prospectively maintained testicular cancer database was queried to identify 
patients who presented with or developed clinical stage II sex cord stromal tumors and 
underwent RPLND at our institution between 1980 and 2018.  Demographic, clinical and 
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pathological characteristics were reviewed.  Kaplan-Meier curves were graphed to assess 
recurrence-free and overall survival. 
Results:  Fourteen patients were included in the study with a median age of 44.2 years.  Four 
patients presented with clinical stage II disease and 10 patients developed metastatic disease 
during follow-up of initial clinical stage I disease with a median time to metastasis of 2.7 years 
(range: 0.4-19.5 years).  Of the 10 patients with orchiectomy pathology data available, all 
patients had at least 1 risk factor on testis pathology (mean: 2.9 risk factors). Nine patients 
received treatment prior to referral to our institution.  All patients recurred post-RPLND at 
Indiana University.  Median recurrence-free survival was 9.8 months.  Twelve patients died of 
disease with a median overall survival of 14.4 months.   
Conclusions:  Metastatic sex cord stromal tumors are rare and are more resistant to standard 
treatment modalities than metastatic germ cell tumors. Patients presenting with sex cord stromal 
tumors should consider prophylactic primary RPLND in the setting of one or more pathological 
predictor of malignancy. 
Keywords: Testicular Cancer, Sex Cord Stromal Tumors, Metastatic Disease, Retroperitoneal 
Lymph Node Dissection, Recurrence, Pathology 
 
 
 
Abbreviations: CS – Clinical Stage; RPLND – Retroperitoneal Lymph Node Dissection; NDI – 
National Death Index; mTOR – mammalian target of rapamycin 
 
Introduction: 
Testicular cancer is the most common solid malignancy in men aged 15-44 with an estimated 
9,310 new diagnoses in the United States in 2018 
1
.  The overwhelming majority of these new 
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cases (~95%) are histologically classified as germ cell tumors.  The remaining cases (~5%) 
predominantly are classified as sex cord stromal tumors (Sertoli or Leydig Cell) 
2,3
.  Most sex 
cord stromal tumors are benign and orchiectomy alone is curative suggesting that surveillance is 
the most appropriate management strategy for the majority of men presenting Clinical Stage 
(CS) I disease 
4
.  However, 10% of sex cord stromal tumors exhibit malignant behavior.  
Pathological risk factors as outlined by Lee et al. have been proposed to better select the 10% of 
patients who exhibit malignant behavior who may benefit from further therapy 
5
.  However, little 
is known regarding the best treatment approach for patients presenting with or developing 
metastatic disease during surveillance.   
 
The discovery of the combination of cisplatin-based chemotherapeutic regimens and 
aggressive retroperitoneal surgery when warranted for the treatment of men with metastatic germ 
cell tumors is arguably one of the most significant advances in cancer care in the last half century 
6
.  Previous to this, men with metastatic germ cell tumors had dismal survival rates of 5-10% 
which drastically improved to the modern rates ranging from 75% to greater than 90% 
7,8
.  
However, the efficacy of chemotherapy and aggressive surgery for the rare man presenting with 
or developing metastatic sex cord stromal tumors is limited to case studies and small case series 
which all report uninspiring results 
4,9
. 
 Thus, in this study, we sought to describe our experience managing patients with CS II 
sex cord stromal tumors and report oncological outcomes after retroperitoneal lymph node 
dissection (RPLND).   
 
Materials and Methods: 
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Patient Selection: 
 
The Indiana University prospectively maintained and institutional review board approved 
testicular cancer database was queried to identify patients who presented with or developed CS II 
sex cord stromal tumors and underwent RPLND at our institution between 1980 and 2018.  
Patients were excluded if a definitive pathological diagnosis of a sex cord stromal tumor was 
unable to be confirmed or if the RPLND was performed for CS I disease.  The records of the 
included patients were reviewed.  Referring physicians and living patients were directly 
contacted and interviewed.  Referring physicians and hospital systems of deceased patients were 
contacted for medical records regarding treatment course from the time of RPLND until their last 
follow-up or death.  Pertinent information obtained included date and location of recurrence, 
treatment at initial recurrence, treatment and site of further recurrences, and date of last follow-
up. 
 
Orchiectomy Pathologic Risk Factors: 
 
The pathology reports were reviewed if available and assessed for pathological risk 
factors of aggressive disease as previously defined by Kim et al 
5
.  These risk factors included: 
tumor size > 5 cm, presence of necrosis, moderate or severe nuclear atypia, lymphovascular 
invasion, infiltrating margins and > 5 mitotic features per 10 high powered fields.  
 
Primary and Secondary Outcomes: 
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The primary outcome was to assess how aggressive retroperitoneal surgery impacted 
recurrence-free and overall survival.  Vital status, cause of death and date of death were obtained 
using the National Death Index (NDI).  The NDI is a centralized database of death record 
information established by the National Center for Health Statistics to aid epidemiologists and 
medical investigators with mortality ascertainment 
10
.  Recurrence-free survival was calculated 
from the date of the RPLND until the date of initial recurrence if known.  If the date of 
recurrence was unknown and the patient died of disease, recurrence-free survival was calculated 
from the time of RPLND until the time of death.  Overall survival was calculated from the time 
of RPLND until the time of death.  Patients with unknown death dates or patients still alive were 
censored at the time of last follow-up or last patient contact, whichever occurred later.  
Secondary outcomes include the description of recurrence patterns and the association between 
pathological risk factors in orchiectomy specimens with the development of metastatic disease. 
 
Statistical Analysis: 
 
Descriptive statistics including means and standard deviations (or median and ranges) 
and counts and frequencies were used to summarize continuous and categorical variables for the 
entire cohort, respectively.  Median recurrence-free and overall survival were calculated and 
survival curves were graphed using the Kaplan-Meier method.  All statistical analysis was 
conducted using SAS 9.4 (SAS Institute, Cary, NC). 
 
Results: 
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Patient Characteristic and Clinical Course Prior to RPLND: 
 
Overall 14 patients were included in this study.  Pertinent data for the entire cohort is 
summarized in Table 1.  The median age at initial diagnoses was 44.2 years (range: 14-67).   The 
laterality of the primary tumor was left and right in seven patients each.  Histology of the 
orchiectomy was Sertoli Cell in 6, Leydig in 3 and Sex Cord Unclassified in 5.  Ten (71.4%) 
men developed CS II disease during surveillance whereas 4 (29.6%) men presented with CS II at 
initial presentation.  The median time to metastasis in men with initial CS I disease was 2.7 years 
(range 0.4-19.5 years).  Nine men had treatment prior to RPLND at our institution with some 
men having multimodal therapy.  RPLND at an outside institution occurred in 4 men, whereas 5 
were treated with systemic chemotherapy and 4 received retroperitoneal external beam radiation. 
 
Orchiectomy Pathologic Risk Factors: 
 
The pathology reports of 10 patients were able to be reviewed for known risk factors of 
aggressive disease.  All ten patients had at least one pathological risk factor with a mean number 
of 2.9 risk factors.  The most common risk factor present were moderate atypia (10 patients), 
necrosis (7 patients) and > 5 mitosis (6 patients). 
 
RPLND Outcomes: 
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Prior to RPLND, the retroperitoneal mass size was <2 cm, 2-5 cm, 5-10 cm and >10 cm 
in 2, 3, 4 and 5 patients, respectively.  Four patients underwent postchemotherapy RPLND, 2 
underwent re-do RPLND and 8 underwent primary RPLND.  Ten patients had bilateral template 
dissections, and 4 had modified unilateral dissections.  No patients underwent a nerve-sparing 
procedure.  Additional procedures at the time of RPLND were common including nephrectomies 
(4), bowel resections/repairs (4), aortic graphs (2), retrocrual dissection (2), vena cava resection 
(1), and pelvic dissection (1).  The mean length of stay was 8.84 days (+/- 6.69).  The mean 
number of positive and total lymph nodes removed was 3.3 (+/- 2.26) and 13.3 (+/- 10.1), 
respectively. 
 
Recurrence patterns, Recurrence-Free Survival and Treatment at Recurrence: 
 
All patients recurred postoperatively with a median recurrence-free survival of 9.8 
months (Figure 1).  The recurrence locations included in-field, out-of-field abdominal and extra-
abdominal (Table 1).  Four patients received adjuvant chemotherapy immediately after the 
RPLND and two additional patients were known to receive multiple chemotherapy regimens for 
recurrence.  Four patients underwent subsequent surgeries for recurrences including 1 patient 
who underwent multiple procedures including a hepatectomy (2), omentectomy, pelvic mass 
resection, paracolic and colon resection, re-do RPLND, and a splenectomy.  The additional 
surgeries of the other three patients are listed in Table 1.   
 
Overall Survival: 
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Twelve (85.7%) of the patients died of disease with a median overall survival of 14.4 
months (Figure 1).  The two patients who are currently alive are living with disease and on 
investigational treatments 24 and 46 months since the time of RPLND, respectively.   One of the 
living patients recurred diffusely in the retroperitoneum.  His tumor was sent for genomic 
analysis which indicated a susceptibility to Apalutamide, an androgen receptor antagonist, for 
which he has been taking for the last 4 months.  The other living patient has undergone multiple 
surgeries and chemotherapeutic regimens since his RPLND.  Notably, this patient’s tumor was 
also sent for genomic analysis which indicated a susceptibility to Everolimus which is a 
mammalian target of rapamycin (mTOR) inhibitor.  Treatment with this medication resulted in 
stable or slightly regressing metastatic disease for 12 months. 
 
Comment: 
 
Our current study describes the natural history of patients presenting with or developing 
metastatic sex cord stromal tumors.  Over a nearly four-decade period, only 14 patients met this 
inclusion criteria highlighting the rarity of this aggressive phenotype.  However, when metastatic 
disease occurs, recurrence-free and overall survival after aggressive retroperitoneal surgery was 
9.8 and 14.4 months, respectively.  Our results suggest that metastatic sex cord stromal tumors 
are resistant to multimodal cisplatin-based chemotherapy, aggressive surgical resection and 
radiotherapy which drastically contradicts the life-saving capabilities of these treatment 
modalities in men with germ cell tumors.  As a result of these poor outcomes in the setting of 
metastatic disease, patients presenting with CS I sex cord stromal tumors should consider 
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prophylactic primary RPLND in the setting of one or more pathological predictors of 
malignancy. 
 
Recently, the National Cancer Database was utilized to evaluate patterns of care and 
survival outcomes for men diagnosed with sex cord stromal tumors.  Over a 12-year period, only 
315 cases (0.39% of all testicular cancer cases) were identified with the majority being Leydig 
Cell tumors.  A few interesting trends were observed.  First, regardless of tumor histology, men 
with CS I disease had lower 5-year Overall Survival then what would be expected for men with 
germ cell tumors (5-year OS for Leydig, 91%; Sertoli 77%).  Second, the majority of men with 
CS I disease did not receive adjuvant treatment after orchiectomy.  Third, even when analyzing a 
population-based database, investigation into treatment trends and response for men with CS II 
was impossible as only 30 men had at least CS II disease 
11
.  This analysis suggests that given the 
inferior survival outcomes, increasing the utilization of RPLND for CS I disease may be of 
potential benefit.  A major limitation in the analysis, however, was the inability to investigate 
pathological risk factors of aggressive disease in orchiectomy specimens which has been 
proposed as a selection criteria for patients who should consider adjuvant therapy 
5,9
. 
 
 The importance of pathological risk factors in orchiectomy specimens has been 
investigated in other case series.  In a case series of 38 patients diagnosed with sex cord stromal 
tumors over a 25-year period in England, high-risk orchiectomy features were rarely observed 
and patients universally were cured with orchiectomy alone 
12
.  Similarly, 37 of 48 patients 
diagnosed with sex cord stromal tumors and managed at Memorial Sloan Kettering over a 15-
year period had 0 or 1 pathological risk factors.  All of these patients were managed with 
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observation after orchiectomy and none of the patients recurred or progressed with relatively 
short follow-up (14.5 months) 
9
.  These results suggest that orchiectomy alone is curative in men 
in the absence of pathological risk factors.   Conversely, six men in the cohort from Memorial 
Sloan Kettering with 2 high-risk orchiectomy features and CS I disease underwent prophylactic 
RPLND.  Two of these men were found to have disease recurrence and progression after RPLND 
and ultimately died of their disease.  Moreover, men with high-risk features on orchiectomy who 
were initially observed and underwent RPLND at the time of recurrence universally developed 
disease recurrence and progression 
9
.   The poor results of RPLND for men at the time of disease 
progression after initial observation were further confirmed in two other studies 
4,13
.   
Collectively, these studies support the findings of our current study.  RPLND at the time of CS II 
disease is associated with poor outcomes and arguably should be done only in highly selected 
situations.  Risk features on orchiectomy appear to have a predictive ability to identify patients 
that may recur during periods of observation.   The number of risk features in the orchiectomy (1 
vs 2 or more) for which a primary RPLND should be offered is unknown.  A systematic review 
of 47 studies and 292 patients further confirmed the prognostic importance of orchiectomy risk 
factors.  Men with CS I disease and >2 risk factors had a 5-year DFS of 44.9% which was 
drastically lower than those with 1 or less risk factor.  However, men with only 1 risk factor 
made up 11.1% of all recurrences therefore suggesting that a more conservative cut-off of 1 or 
more risk factor as a criteria for RPLND is reasonable 
14
.  Whether or not the lack of risk factors 
is universally predictive of benign behavior is speculative.  
 
 The current study must be viewed in the context of certain limitations.  First, the strength 
of evidence of a single institution small case series is low.  Given the rarity of the disease, the 
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ability to perform randomized controlled trials investigating treatment regimens is unrealistic.  
Further work on this matter should focus on multi-institutional pooling of patients to further 
strengthen and improve the generalizability of the results.  However, given the small number of 
CS II sex cord stromal tumors identified using population databases, the importance of single 
institutional case series for rare diseases or clinical situations remains 
11
.  Second, the pattern of 
recurrence and treatment at time of recurrence is unknown for a portion of the patients in our 
cohort.  We attempted to mitigate this by directly contacting referring physicians and healthcare 
systems. Nevertheless, our primary conclusions remain valid due to the retrieval of vital status 
and cause of death (if applicable) information for the entire cohort.  
 
 These limitations notwithstanding, we believe that the results of our study sufficiently 
adds to the body of literature by describing the clinical history after RPLND for men with CS II 
sex cord stromal tumors.  Men who present with or develop macroscopic metastatic sex cord 
stromal tumors comparatively do worse than men diagnosed with metastatic germ cell tumors.  
The oncological benefit of aggressive multimodal treatment in these men is debatable.  Deciding 
to proceed with aggressive surgery in this cohort should only be done in select situations after 
multidisciplinary discussion.  The fate of men with microscopic metastatic disease at initial 
presentation remains unknown and the role of surgical therapy in this cohort is speculative; 
however, due to the lack of effective therapies for metastatic disease, providers and patients 
should consider primary RPLND for CS I disease with 1 or more pathological risk factor for 
malignancy.   Due to the high discrepancy of pathological interpretation between community 
hospitals and tertiary referral centers for germ cell tumors, we suggest that all sex cord stromal 
tumors are pathologically reviewed for the presence of adverse factors and primary RPLNDs 
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performed, if advised, at centers with extensive experience managing advanced testicular cancer 
15
. 
 
Conclusion: 
 
 Metastatic sex cord stromal tumors are rare.  In our experience, aggressive retroperitoneal 
surgery in men with macroscopic metastatic disease is not associated with the same oncological 
efficacy as surgery in men with germ cell tumors.  Given the lack of effective therapies for men 
with macroscopic metastatic disease, we suggest considering prophylactic primary RPLND in 
men with 1 or more pathological risk factors for malignancy.   
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Figure 1: Recurrence-free (RFS) and Overall Survival (OS) in men with Clinical Stage II 
Sex Cord Stromal Tumors treated with Retroperitoneal Lymph Node Dissections 
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Table 1: Patient-Specific Clinical Characteristics and Treatment Course of the Study Cohort 
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+ Patients dead of disease but death date unknown; censored at time of last follow-up 
++ Patients current vital status living; censored at time of last follow-up 
 
 
 
 
